Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2020 16:05 ET | Source: Equillium

Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
November 10, 2020 08:35 ET | Source: Equillium

Equillium to Present at Investor Conferences in November 2020

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
November 04, 2020 08:35 ET | Source: Equillium

Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Studies further validate ongoing clinical development of itolizumab for the treatment of systemic lupus erythematosus and lupus nephritis LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) --...
September 03, 2020 16:07 ET | Source: Equillium

Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference

LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
August 18, 2020 16:05 ET | Source: Equillium

Equillium Announces Closing of Public Offering of Common Stock

LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
July 30, 2020 16:07 ET | Source: Equillium

Equillium to Present at BTIG Virtual Biotechnology Conference 2020

LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
May 21, 2020 16:07 ET | Source: Equillium

Equillium to Present at Jefferies Virtual Healthcare Conference

LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
May 13, 2020 16:07 ET | Source: Equillium

Equillium Reports First Quarter 2020 Financial Results

LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
May 07, 2020 16:07 ET | Source: Equillium

Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference

LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
March 30, 2020 16:07 ET | Source: Equillium

Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...